(RTTNews) – Shares of Quotient Ltd. (QTNT) jumped 31.62% to $9.99 in after-hours trading on April 27, after the company reported a very strong final study performance data for its SARS-CoV-2 antibody test.

The company noted that it expects to complete the CE marking process and the submission of the FDA emergency use authorization for the MosaiQ COVID-19 Antibody Microarray in the next few days. Discussions with potential customers in Europe and the US are ongoing.

“I am very pleased with the exceptional results from our final study’s performance data. Our innovative MosaiQ technology delivered 100% sensitivity and 99.4% specificity, truly an outstanding performance. We are confident that we will CE mark for Europe including Switzerland and begin the FDA emergency use authorization process within a matter of days,” said Franz Walt, Chief Executive Officer of Quotient.

The stock has been trading between $2.40 and $11.30 in the past one year, and closed Monday’s trade at $7.59, up $1.08 or 16.59%. QTNT, further, gained $2.40 or 31.62% in the extended trading session.

All your Asset management needs with Global Asset Management Seoul Magazine

This post was originally published on this site


Comments are closed.